Passage BIO, Inc. (PASG): Entry into a Material Definitive Agreement
Passage BIO, Inc. (PASG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Amended and Restated Merger Agreement As previously disclosed, on June 24, 2026, Passage Bio, Inc. (“ Passage Bio ” or the “ Company ”), Peregrine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the
How this was made
The 30-second read
Why it matters
The amendment secures needed capital and clarifies the merger timeline, but introduces new warrant dilution risk.
Market read
Primary disclosure of a material merger amendment for a micro‑cap biotech, relevant for investors tracking deal pipelines.
What to watch
Potential tax benefits of the two‑step structure and the timing of the $70 M financing could improve balance‑sheet strength.
Background
Passage BIO previously announced a merger with Remix Therapeutics; this filing updates the agreement and financing terms.
Ticker impact
Passage BIO filed an 8‑K announcing an amended and restated merger agreement and a $70 M concurrent financing.
Short‑term volatility expected; price may dip on dilution concerns, then stabilize as deal progresses.
Deal terms unchanged materially, but new financing and warrant structure introduce execution risk.
Market effects
Biotech M&A activity may increase as smaller firms seek capital via merger structures.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech merger market.
Counterpoint
The added pre‑funded warrants could heavily dilute existing shareholders, making the deal less attractive.
Key entities
- CompanyPassage BIO, Inc.
Biotech firm executing the merger.
- CompanyRemix Therapeutics, Inc.
Target company in the merger.
